QPS collaborated with Sumitomo Pharmaceuticals America Inc. to develop and validate a sensitive LC-MS/MS method for relugolix quantification in human plasma and its application to a clinical study.

QPS collaborated with Gilead Sciences, Inc. to validate a method to measure FTC-TP and TFV-DP levels in human PBMCs, using gDNA-calibrated PBMC counts to express results in ng per million cells.

QPS worked closely with Omnix Medical Ltd. to present the results of a Phase I first-in-human study in healthy volunteers with intravenously administered OMN6.

Peter Dogterom, PhD presents the Phase 1 evaluation of the safety, tolerability and plasma and CSF pharmacokinetics of AST-004 after IV infusion in healthy volunteers.

Peter Dogterom, PhD presents the relative bioavailability and food effect study with a new tablet formulation of selvigaltin (GB1211) in healthy volunteers.

Peter Dogterom, PhD presented Experiences of CSF collection by serial sampling or lumbar puncture in clinical pharmacology research at ASCPT 2023 in March 2023.

Michael Sonnenfelt presented Partial Method Validation of Biomarker Assays to Determine Adrenocorticotropic Hormone (ACTH) Concentrations in Rat and Canine Serum in Support of Pre-Clinical Endocrinology Drug Development in collaboration with Crinetics, at WRIB in June 2023.